Skip to main content
SpringerLink
Log in

In silico prediction coupled with in vitro experiments and absorption modeling to study the inclusion complex of telmisartan with modified beta-cyclodextrin

  • Original Article
  • Published:
Journal of Inclusion Phenomena and Macrocyclic Chemistry Aims and scope Submit manuscript

Abstract

Telmisartan (TEL) is a poorly bioavailable antihypertensive drug candidate owing to its low solubility in all the biofluids. The present study is aimed to enhance the solubility of TEL by forming an inclusion complex with sulfobutylether beta-cyclodextrin (SBE-β-CD), discover its mode of inclusion and predict the bioavailability of the prepared complexes. The formation of the inclusion complex is explained based on the hydrogen bond propensities and molecular dynamics simulations. Freeze-drying method was employed for the preparation of inclusion complexes. These complexes were subsequently characterized by powder X-ray diffraction, differential scanning calorimetry, and Fourier transform-infrared spectroscopy. The spatial configuration of the drug inside the cyclodextrin cavity is probed using 1H and 13C NMR. The in silico docking results are in good agreement with the experimental data and reveal that the hydrogen bond is formed as a part of the guest molecule enters from the broader end of the ring and the protons at the interior portion of the molecule interact with the carboxylic acid (–COOH) group of TEL leading to the formation of a hydrogen bond. The phenyl moiety of TEL occupies the central core and forms multiple Van-der-Waals interactions with the glucopyranose units of the SBE-β-CD. The inclusion complex demonstrates significantly higher in vitro dissolution profile as compared with plain TEL. The GastroPlus™ simulation software generated parameters of inclusion complex in comparison to plain TEL show a seven fold increase in Cmax and 18 fold increase in bioavailability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

Similar content being viewed by others

References

  1. Wienen, W., Entzeroth, M., Meel, J.C.A., Stangier, J., Busch, U., Ebner, T., Schmid, J., Lehmann, H., Matzek, K., Kempthorne-Rawson, J., Gladigau, V., Hauel, H.N.: A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc. Drug. Rev. 18, 127–154 (2006)

    Article  Google Scholar 

  2. Kaur, M., Bhatia, R.K., Pissurlenkar, R.R.S., Coutinho, E.C., Jain, U.K., Katare, O.P., Chandra, R., Madan, J.: Telmisartan complex augments solubility, dissolution and drug delivery in prostate cancer cells. Carbohydr. Polym. 101, 614–622 (2014)

    Article  CAS  Google Scholar 

  3. Abali, H., Güllü, I.H., Engin, H., Haznedaroğlu, I.C., Erman, M., Tekuzman, G.: Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med. Hypotheses 59, 344–348 (2002)

    Article  CAS  Google Scholar 

  4. Sharpe, M., Jarvis, B., Goa, K.L.: Telmisartan: a review of its use in hypertension. Drugs 61(10), 1501–1529 (2001)

    Article  CAS  Google Scholar 

  5. McClellan, K.J., Markham, A.: Telmisartan. Drugs 56(6), 1039–1044 (1998)

    Article  CAS  Google Scholar 

  6. Park, J., Park, H.J., Cho, W., Cha, K.-H., Yeon, W., Kim, M.S., Kim, J.S., Hwang, S.: Comparative study of telmisartan tablets prepared via the wet granulation method and prior? Prepared using the spray-drying method. J. Arch. Pharm. Res. 34, 463–468 (2011)

    Article  CAS  Google Scholar 

  7. Tran, P.H.L., Tran, H.T.T., Lee, B.J.: Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J. Control. Rel. 129, 59–65 (2008)

    Article  CAS  Google Scholar 

  8. Sangwai, M., Vavia, P.: Amorphous ternary cyclodextrin nanocomposites of telmisartan for oral drug delivery: improved solubility and reduced pharmacokinetic variability. Int. J. Pharm. 453, 423–432 (2013)

    Article  CAS  Google Scholar 

  9. Van Hoogevest, P., Liu, X., Fahr, A.: Drug delivery strategies for poorly water-soluble drugs: the industrial perspective Expert Opin. Drug Deliv. 8(11), 1481–1500 (2011)

    Article  Google Scholar 

  10. Singh, A., Worku., Z.A., Van den Mooter, G.: Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin. Drug Deliv. 8(10), 1361–1378 (2011)

    Article  CAS  Google Scholar 

  11. Davis, M.E., Brewster, M.E.: Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3, 1023–1035 (2004)

    Article  CAS  Google Scholar 

  12. Zia, V., Rajewski, R.A., Stella, V.: Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7M-beta-CD to HP-beta-CD. J. Pharm. Res. 18, 667–673 (2001)

    Article  CAS  Google Scholar 

  13. Irie, T., Uekama, K.: Pharmaceutical applications of cyclodextrins: III: toxicological issues and safety evaluation. J. Pharm. Sci. 86, 147–162 (1997)

    Article  CAS  Google Scholar 

  14. Thompson, D.O.: Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 14, 1–104 (1997)

    Article  CAS  Google Scholar 

  15. Dinnebier, R.E., Sieger, P., Nar, H., Shankland, K., David, W.I.F.: Structure characterization of three crystalline modifications of telmisartan by single crystal and high-resolution X-ray powder diffraction. J. Pharm. Sci. 89, 1465–1479 (2000)

    Article  CAS  Google Scholar 

  16. Wang, J., Pham, D., Kee, T.W., Clafton, S.N., Guo, X., Clements, P., Lincoln, S.F., Prud’homme, R.K., Easton, C.J.: Aggregation and host–guest interactions in dansyl-substituted poly(acrylate)s in the presence of β-cyclodextrin and a β-cyclodextrin dimer in aqueous solution: a UV-Vis, fluorescence, 1H NMR, and rheological study. Macromolecules 44, 9782–9791 (2011)

    Article  CAS  Google Scholar 

  17. Kiwon, O.K., Jung, Y.W., Jee, J., Byun, Y.: Facile docking and scoring studies of carborane ligands with estrogen receptor. Bull. Korean Chem. Soc. 34, 1051–1054 (2013)

    Article  Google Scholar 

  18. Galek, P.T.A., Fabian, L., Allen, F.H.: Universal prediction of intramolecular hydrogen bonds in organic crystals. Acta Crystallogr. B 66, 237–252 (2010)

    Article  CAS  Google Scholar 

  19. Wood, P.A., Feeder, N., Furlow, M., Galek, P.T.A., Groom, C.R., Pidcock, E.: Knowledge-based approaches to co-crystal design. CrystEngComm 16, 5839–5848 (2014)

    Article  CAS  Google Scholar 

  20. Martiny, V.Y., Martz, F., Selwa, E., Lorga, B.I.: Blind pose prediction, scoring, and affinity ranking of the CSAR 2014 dataset. J. Chem. Inf. Model. S6, 996–1003 (2016)

    Article  Google Scholar 

  21. Higuchi, T., Connors, K.A.: Phase solubility techniques. Adv. Anal. Chem. Instrum. 4, 117–212 (1965)

    CAS  Google Scholar 

  22. Williams, R.O., Mahaguna, V., Sriwongjanya, M.: Characterization of an inclusion complex of cholesterol and hydroxypropyl-beta-cyclodextrin. Eur. J. Pharm. Biopharm. 46, 355–360 (1998)

    Article  CAS  Google Scholar 

  23. Klein, S.: The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 12, 397–406 (2010)

    Article  CAS  Google Scholar 

  24. Zoeller, T., Dressman, J.B., Klein, S.: Application of a ternary HP-β-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions. Int. J. Pharm. 430, 176–183 (2012)

    Article  CAS  Google Scholar 

  25. Fagerberg, J.H., Tsinman, O., Sun, N., Tsinman, K., Avdeef, A., Bergstrom, C.A.S.: Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol. Pharm. 7, 1419–1430 (2010)

    Article  CAS  Google Scholar 

  26. George, J.K., Singh, S.K., Verma, P.R.P.: In vivo in silico pharmacokinetic simulation studies of carvedilol-loaded nanocapsules using GastroPlus. Ther. Deliv. 7, 305–318 (2016)

    Article  CAS  Google Scholar 

  27. Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi, T., Sugiyama, Y.: Predominant contribution of OATP1b3 to the hepatic uptake of telmisartan, an angiotensin ii receptor antagonist, in humans. Drug Metab. Dispos. 34, 1109–1115 (2006)

    Article  CAS  Google Scholar 

  28. Stangier, J., Schmid, J., Türck, D., Switek, H., Verhagen, A., Peeters, P.A., van Marle, S.P., Tamminga, W.J., Sollie, F.A., Jonkman, J.H.: Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers. J. Clin. Pharmacol. 40, 1312–1322 (2000)

    CAS  Google Scholar 

  29. Li, R., Barton, H.A., Maurer.:, T.S.: A Mechanistic Pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions. CPT 4, 338–349 (2015)

    CAS  Google Scholar 

  30. Stangier, J., Su, C.P.F., Schöndorfer, G., Roth, W.: Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J. Clin. Pharmacol. 40, 1355–1364 (2000)

    CAS  Google Scholar 

  31. De Buck, S.S., Sinha, V.K., Fenu, L.A., Nijsen, M.J., Mackie, C.E., Gilissen, R.A.H.J.: Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. 35, 1766–1780 (2007)

    Article  Google Scholar 

  32. Grandelli, H.E., Stickle, B., Whittington, A., Kiran, E.: Inclusion complex formation of β-cyclodextrin and naproxen: a study on exothermic complex formation by differential scanning calorimetry. J. Incl. Phenom. Macrocycl. Chem. 77, 269–277 (2013)

    Article  CAS  Google Scholar 

  33. Bisson-Boutelliez, C., Fontanay, S., Finance, C., Kedzierewicz, F.: Preparation and physicochemical characterization of amoxicillin beta-cyclodextrin complexes. AAPS PharmSciTech 11, 574–581 (2010)

    Article  CAS  Google Scholar 

  34. Ge, X., Huang, Z., Tian, S., Huang, Y., Zeng, C.: Complexation of carbendazim with hydroxypropyl-β-cyclodextrin to improve solubility and fungicidal activity. Carbohydr. Polym. 89, 208–212 (2012)

    Article  CAS  Google Scholar 

  35. Zhang, Y., Zhi, Z., Jiang, T., Zhang, J., Wang, Z., Wang, S.: Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J. Control. Release 145, 257–263 (2010)

    Article  CAS  Google Scholar 

  36. Chella, N., Narra, N., Rama Rao, T.: Preparation and characterization of liquisolid compacts for improved dissolution of telmisartan. J. Drug Deliv. 2014, 692793 (2014)

    Article  Google Scholar 

  37. Zhao, R., Tan, T., Sandstrorm, C.: NMR studies on puerarin and its interaction with beta-cyclodextrin. J. Biol. Phys. 37, 387–400 (2011)

    Article  CAS  Google Scholar 

  38. Ieiri, I., Nishimura, C., Maeda, K., Sasaki, T., Kimura, M., Chiyoda, T., Hirota, T., Irie, S., Shimizu, H., Noguchi, T., Yoshida, K., Sugiyama, Y.: Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet. Genom. 21, 495–505 (2011)

    Article  CAS  Google Scholar 

  39. Yamada, A., Maeda, K., Ishiguro, N., Tsuda, Y., Igarashi, T., Ebner, T., Roth, W., Ikushiro, S., Sugiyama, Y.: The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet. Genom. 21, 523–530 (2011)

    Article  CAS  Google Scholar 

  40. Fagerholm, U.: Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation. J. Pharm. Pharmacol. 60, 535–542 (2008)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, India

    Abhishek Chandra, M. Vivek Ghate & Shaila A. Lewis

  2. International Center for Applied Sciences, Manipal Academy of Higher Education, Manipal, 576104, India

    K. S. Aithal

Authors
  1. Abhishek Chandra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Vivek Ghate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. S. Aithal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shaila A. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaila A. Lewis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chandra, A., Ghate, M.V., Aithal, K.S. et al. In silico prediction coupled with in vitro experiments and absorption modeling to study the inclusion complex of telmisartan with modified beta-cyclodextrin. J Incl Phenom Macrocycl Chem 91, 47–60 (2018). https://doi.org/10.1007/s10847-018-0797-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10847-018-0797-x

Keywords

Search

Navigation